Overview

• MajesTEC-3 tested teclistamab plus subcutaneous daratumumab in relapsed or refractory multiple myeloma after 1 to 3 prior therapies.
• The combo outperformed daratumumab-based standards with dexamethasone plus pomalidomide (DPd) or bortezomib (DVd) at the first interim analysis.
• An independent data monitoring committee recommended halting and unblinding the study after prespecified objectives were met.
• After roughly three years of follow-up, J&J reported statistically significant progression-free survival gains with a clear overall survival advantage.
• Safety was consistent with known profiles for each drug, and detailed results will be presented at a medical meeting and submitted to regulators.